A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.
about
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to ExpectEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisStatistical Methods for Establishing Personalized Treatment Rules in OncologyMouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studiesGenetic and epigenetic traits as biomarkers in colorectal cancerEmerging technologies for studying DNA methylation for the molecular diagnosis of cancerBayesian predictive modeling for genomic based personalized treatment selection.Literature review and practical aspects on the management of oxaliplatin-associated toxicity.Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility studyEstablishment of new predictive markers for distant recurrence of colorectal cancer using lectin microarray analysis.High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma – a report of a caseMolecular events in primary and metastatic colorectal carcinoma: a review.Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia.Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinomaBiomarkers, bundled payments, and colorectal cancer care.Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.Prognostic value of innate and adaptive immunity in colorectal cancer.Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series.Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo.Alternate dosing of cetuximab for patients with metastatic colorectal cancer.The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.Thioredoxin-like protein 2 is overexpressed in colon cancer and promotes cancer cell metastasis by interaction with ran.Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colonPrognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer.Prognostic Value of E-cadherin-, CD44-, and MSH2-associated Nomograms in Patients With Stage II and III Colorectal Cancer.Interferon-induced transmembrane protein 1 (IFITM1) is required for the progression of colorectal cancer.KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancerCell surface markers in colorectal cancer prognosis.Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI.Promoter CpG island methylation markers in colorectal cancer: the road ahead.Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.Molecular markers for colon diagnosis, prognosis and targeted therapy.Biomarkers of colorectal cancer: recent advances and future challenges.Early detection of colorectal cancer: from conventional methods to novel biomarkers.Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial.
P2860
Q26775578-3BF7F0A9-10BE-4E5F-B651-82F9ED51A01EQ26777704-D9BCE053-9B03-4B7B-BFAB-7E84049B8D63Q26786366-C0D8A541-EFAF-4C6E-B1B2-6306C16CBBBCQ27008537-ECD7987B-CB18-4DEB-A85B-4D11F2CA3C5EQ27016019-0E24EF6E-4D42-4B34-807D-FF116513EEE3Q28087759-80955CA1-C9C6-4AF7-9233-D34ED3476255Q30758322-4146987B-D390-4BD2-A816-41EC449B7ADCQ33398649-BDA667FB-E76C-4B75-8EE5-48B71BD47500Q34426265-85D662AC-AF8E-4130-A826-4B9351DCE1DBQ35084954-E9978791-773B-4E7E-9635-E5A9E6E195ACQ35104374-40B66FFC-6EE8-464C-AD4F-C0D1E680A616Q35552209-7488E848-B840-4222-B037-6EBDF9D7C1B8Q35977849-8791DD52-859F-447C-9E5D-42D6BF2A1254Q36093878-63A6F314-4944-4073-B935-7379C22D728DQ36095281-A62D403F-E3AF-4185-93D4-0411ADBF5370Q36153320-474625C7-6157-45CD-AA12-915EA53095ECQ36299382-7F0669B4-8385-4414-96D1-FD4C2FDD05C1Q36541196-D9AA9670-75B7-45C4-887F-453AAA56DDBBQ36551120-661DB9EC-EE6A-4EC4-85A5-052AD48EF402Q36671874-B1C48B45-6CA3-4D36-A517-FF744645000DQ36776983-F0B4A9B7-426A-49C8-854D-5B249D6E1B96Q36895487-ABA0A5B1-1C60-4D1C-ADE3-39FCE590F0EDQ36907279-1DA437C8-B063-4C5D-B20A-E89DC667E561Q37130603-1862934E-F648-4395-A91F-53B79457CCC8Q37147685-FF737F48-22C5-40BB-ACDC-C1CC5D070BDAQ37269345-2C67D030-9EED-4B5D-89BC-0D9317C311CDQ37594945-E5DD0FE3-7F0C-4233-B572-2A5ACCB4A26AQ37600725-D4C07DD1-EDF7-45CF-A2B5-D73654E4DEE1Q37699175-A7C322E8-5A47-4188-B051-9E5390D0A6D2Q37709450-E118F4D1-AC7A-4A71-AA36-6520D6C35EC1Q37711623-E0583164-9A0F-40DE-9C26-C159850B5A74Q37845669-9B51CC18-28E4-4515-AB46-1C94793B14B7Q37880662-F37A7FE2-4CCA-4EEB-88CC-88F98D221589Q37997086-E0B7F800-09CA-47A5-87C2-B9B8689BB970Q38217738-0D8A0CD4-1411-4C88-81CE-07657D6E4541Q38258269-81AE4EED-166E-46C7-9C73-224D7123C469Q38259770-3CAA94DA-EBDC-49B1-B04D-55BCCEAA1873Q38357717-AB2BA366-8A06-451C-86E4-DB7D575735C1Q38582586-E0269322-F599-4A15-AB39-09115479A4FCQ38848171-2B722CB7-62B0-43F5-8937-E719B0BC57D5
P2860
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A review of the most promising ...... ep closer to targeted therapy.
@ast
A review of the most promising ...... ep closer to targeted therapy.
@en
type
label
A review of the most promising ...... ep closer to targeted therapy.
@ast
A review of the most promising ...... ep closer to targeted therapy.
@en
prefLabel
A review of the most promising ...... ep closer to targeted therapy.
@ast
A review of the most promising ...... ep closer to targeted therapy.
@en
P2860
P50
P1433
P1476
A review of the most promising ...... ep closer to targeted therapy.
@en
P2093
Jan B Vermorken
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0025
P577
2010-06-28T00:00:00Z